AB0427 ADHERENCE ANALYSIS OF REAL-WORLD EVIDENCE FOR ADALIMUMAB BIOSIMILAR MSB11022 THERAPY IN RHEUMATOLOGIC DISEASES
Authors: S. Cheung, D. Truong
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Phase III clinical trial results demonstrated evidence of safety and efficacy data are similar between MSB11022 (an adalimumab biosimilar) and reference adalimumab in patients with moderate to severe rheumatoid arthritis (RA)<sup>[1]</sup>. Adherence to biologic treatments is often indicative of disease control and good patient treatment experience. However, evidence on the adherence for MSB11022 in rheumatology diseases is lacking in real-world clinical care setting. <h3>Objectives</h3> The objective of this project was to analyze real-world data collected by Fresenius Kabi patient-support program (PSP, KabiCare) on adherence to MSB11022. Patients with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) were included in this analysis. <h3>Methods</h3> Patients with RA, PsA and AS enrolled in KabiCare and received at least one dose of adalimumab biosimilar, MSB 11022, were follow-up from Feb 2021 to Nov 2022 in Canada. Medication initiation date and stop date, disease types and patient treatment (categorized by naïve to biologic or, switched from other biologics) were recorded in the database. The stop date was the date when KabiCare was informed that medication was discontinued. The patients continuing medication were censored at the maximal follow-up date of analysis, November 9, 2022. Log-rank tests were used for KM (Kaplan-Meier) plot comparison to examine if there were differences in medication adherence among RA, PsA and AS, and between naïve group vs. switch group by disease. <h3>Results</h3> The analysis sample consisted of 2049 patients, 879 of whom had RA, 514 had PsA and 656 had AS. Naïve group included 448 RA, 192 PsA and 256 AS patients. KabiCare followed patients for a median time of 260 days (interquartile range: 169-383 days; maximum: 609 days). At 500 days (approximately 18 months) post initiation of medication, the adherence probability was similar for patients with RA, PsA and AS (At day-500: 75.3%, 82.8% and 81.9%, P=0.096). The adherence probability was higher with switch group compared to naïve group (At day-500: 79.9.8% vs. 70.7%, P=0.027 in RA, 88.1% vs. 72.0%, P=0.0011 in PsA, and 85.8% vs. 74.9%, P=0.0057 in AS). <h3>Conclusion</h3> MSB11022 adherence probability for naïve group ranged between 70%-74.9%; and for switched group ranged from 79.9% - 88.1% for RA, PsA, and AS patients combined at 18 months after initiating MSB11022 biologic therapy. This real-world evidence analysis suggests that patients switching to MSB11022, adalimumab biosimilar, will more likely maintain on therapy when compared to patients initiating MSB11022 therapy. In both cases, inflammatory arthritis patients had high adherence to MSB11022 therapy. <h3>Reference</h3> [1] Edwards CJ, Monnet J, Ullmann M, Vlachos P, Chyrok V, Ghori V (2019) Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clinical Rheumatology 38(12):3381-3390 http://pubmed.ncbi.nlm.nih.gov/31396834/ <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Sun Cheung Employee of: Fresenius Kabi Canada, Don Truong Employee of: Fresenius Kabi Canada.